With insurance plans dropping coverage of the drugs, those of us benefiting from them face a costly decision — beyond just the monetary.

Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

A new overview details emerging medical and wellness trends, underscoring advances that broaden treatment access and inform preventive care. GLP-1 drugs such as Ozempic and Wegovy extend to heart, ...

My son is smart - he really is - but he was in love. He and his live-in girlfriend mingled their finances. I'm not sure how much, but now that they've parted, his credit rating is wrecked. Just enough ...

A new study confirms that people taking GLP-1s are more likely to experience hair loss. The good news? It’s probably reversible. Here’s how to deal.

A new review finds no convincing evidence that drugs like Ozempic raise people's risk of common thyroid cancers.

In an interview with The American Journal of Managed Care®, Levin explained that for patients whose medications are covered ...

At Roxborough Memorial Hospital in Philadelphia, surgeon Piotr Krecioch has his hands full launching a program offering surgical interventions to treat obesity. One in three Philadelphians are living ...

Analysts say TrumpRx, the Trump administration's consumer drug-pricing site, might not deliver lower drug prices for most Americans.